Lineage Cell Therapeutics posted GAAP net income of $1.5 million, swinging from a net loss of $30.5 million a year earlier; basic EPS was $0.01.
Revenue fell 61.34% to $1.1 million, due to lower Roche collaboration revenue recognition and lower VAC-related revenue; WDI collaboration revenue partly offset.
Operating loss narrowed 54.9% to $8.9 million, on total operating expenses falling 55.69% to $10 million due to the prior-year $14.8 million VAC impairment.
Cash, cash equivalents, and marketable securities totaled $50.8 million at June 30, expected to fund operations into Q3 2028.
Genentech’s Phase 2a GAlette study for RG6501 remained active at 17 sites; COR1 advanced to in-vivo testing with initial preclinical data expected in 2026.
LCTX•
